Cancer drug prices could double or triple thanks to this popular but unproven drug trend By: MarketWatch June 01, 2017 at 12:48 PM EDT There are nearly 800 immuno-oncology combination trials today, up from around 200 in 2015. Read More >> Related Stocks: Bristol-Myers Squibb Incyte Corp Merck & Co Newlink Genetics Cor Range Cancer Therapeutics Index Standard & Poors 500